Transcatheter Complete Heart Assist Device


The transcatheter complete heart assist device consists of a stent-membrane assembly that can be activated in order to reproduce a pulsatile flow in heart cavities, including both systolic and diastolic phases. The cyclic deformation of the membrane can be adjusted for heart rate and stroke volume depending on patient needs.


  • Minimally invasive surgery
  • Support for left, right or both ventricles
  • Adjustable pulsatile flow
  • Possibility to change the membrane using a stent-in-stent approach in case of failure
  • Original design minimizing hemolysis
  • Scalable design for young or elderly patient
  • For patients with severe CHF as a bridge to transplantation or a destination therapy

Current Status

  • A first prototype of left ventricular assist device (LVAD) was designed and successfully tested in a heart simulator and a bi-ventricular assist device (Bi-VAD) prototype is also in development for severe CHF.


Market opportunities:

  • (CVDs) are the first cause of (31% of all death)
  • Congestive heart failure (CHF) is a the pumping power of the heart
  • 7 million patients with CHF in US with 550,000 new cases each year and mortality up to 50% within 5 years
  • Severe CHF but the number of donors is low, leading to long waiting period
  • Lifesaving option is the use of engineered heart assist devices for

Patents opportunities: US Provisional patent

Business opportunities: partnering/licensing

ecommALIGO: Transcatheter Complete Heart Assist Device